1. Home
  2. AGEN vs TMCI Comparison

AGEN vs TMCI Comparison

Compare AGEN & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$7.85

Market Cap

274.8M

Sector

Health Care

ML Signal

HOLD

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$4.49

Market Cap

292.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGEN
TMCI
Founded
1994
2014
Country
United States
United States
Employees
N/A
450
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
274.8M
292.0M
IPO Year
1999
2021

Fundamental Metrics

Financial Performance
Metric
AGEN
TMCI
Price
$7.85
$4.49
Analyst Decision
Buy
Hold
Analyst Count
2
6
Target Price
$14.50
$4.77
AVG Volume (30 Days)
873.0K
217.3K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
0.96
N/A
Revenue
$42,877,086.00
$212,690,000.00
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
$8.18
P/E Ratio
$7.52
N/A
Revenue Growth
89.95
1.59
52 Week Low
$2.71
$1.17
52 Week High
$8.85
$7.10

Technical Indicators

Market Signals
Indicator
AGEN
TMCI
Relative Strength Index (RSI) 54.50 51.42
Support Level $2.97 $4.28
Resistance Level $8.64 $4.86
Average True Range (ATR) 0.43 0.20
MACD -0.10 -0.02
Stochastic Oscillator 54.07 50.00

Price Performance

Historical Comparison
AGEN
TMCI

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.

Share on Social Networks: